Observational, Multicenter study on long-term Effectiveness and tolerability of aliROcumab (OMERO): an Italian real-life experience
The effectiveness of alirocumab in reducing LDL-C and its favorable safety and tolerability profile have been consistently confirmed in a real-world setting among Italian patients treated for up to 3 years.
Authors
- Lucia Notarianni
- Aldo P. Maggioni (ORCID: https://orcid.org/0000-0003-2764-6779)
- Alberico L. Catapano (ORCID: https://orcid.org/0000-0002-7593-2094)
- Giancarlo Agnelli (ORCID: https://orcid.org/0000-0002-4308-7797)
- Francesco Rossi (ORCID: https://orcid.org/0009-0003-5141-7527)
- Eleonora Consolo (ORCID: https://orcid.org/0009-0003-2138-623X)
Institutions
- University of Milan (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Perugia (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- MultiMedica (IT)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Sanofi (Italy) (IT)
- Link Campus University (IT)
Publication Details
- Journal
- International Journal of Cardiology Cardiovascular Risk and Prevention
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1016/j.ijcrp.2025.200549
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00